< Back to previous page
Researcher
Lisa Moris
- Disciplines:Urology and nephrology not elsewhere classified, Andrology, Cancer biology
Affiliations
- Department of Cellular and Molecular Medicine (Department)
Member
From2 Aug 2020 → 14 Jun 2022 - Laboratory of Molecular Endocrinology (Division)
Member
From1 Aug 2016 → 31 Jul 2020
Projects
1 - 1 of 1
- Clinical and preclinical studies of modulators of high-risk prostate cancer with metastatic potentialFrom1 Aug 2016 → 29 Apr 2022Funding: BOF - doctoral mandates, Private funding of national origin - undefined
Publications
21 - 30 of 53
- The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large bi-institutional cohort(2020)
Authors: Tim Muilwijk, Murat Akand, Lisa Moris, Thomas Gevaert, Hendrik Van Poppel, Maarten Albersen, Steven Joniau
Pages: 704 - 714 - Reply to Francesco Montorsi, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27(2020)
Authors: Lisa Moris
Pages: E193 - E194 - Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer(2020)
Authors: Gaëtan Devos, Lisa Moris, Steven Joniau, Frank Claessens
- Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27(2020)
Authors: Lisa Moris
Pages: E116 - E117 - Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27(2020)
Authors: Lisa Moris
Pages: E120 - E121 - Introducing PIONEER: a project to harness big data in prostate cancer research(2020)
Authors: Muhammad Imran Omar, Monique J Roobol, Maria J Ribal, Thomas Abbott, Paul-Michael Agapow, Sonia Araujo, Alex Asiimwe, Charles Auffray, Irina Balaur, Katharina Beyer, et al.
Pages: 351 - 361 - Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making(2020)
Authors: Lisa Moris
Pages: 4039 - 4058 - Benefits and Risks of Primary Treatments for High -risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review(2020)
Authors: Lisa Moris
Pages: 614 - 627 - Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations(2020)
Authors: Lisa Moris
Pages: 231 - 234 - Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis(2020)
Authors: Gaëtan Devos, Wouter Everaerts, Maarten Albersen, Lisa Moris, Frank Claessens, Gert De Meerleer, Karin Haustermans, Hendrik Van Poppel, Steven Joniau